While not precisely a targeted therapy, immune checkpoint inhibitors (ICIs), primarily targeting programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1), aim to reinvigorate CD8+ cytotoxic T cells to identify and eliminate (neo)antigens presented by tumour cells or antigen-presenting cells. The gene discussed is CD274; the disease is neoplasm.